Brief: Heat Biologics Inc - On Track To Complete Enrollment Of Phase 2 Lung Cancer Trial In Q2 2019 And Report Additional Interim Data In Q4 2019
May 15 (Reuters) - Heat Biologics Inc HTBX.O :
* HEAT BIOLOGICS INC - ON TRACK TO COMPLETE ENROLLMENT OF
PHASE 2
LUNG CANCER TRIAL IN Q2 2019 AND REPORT ADDITIONAL INTERIM DATA
IN Q4 2019
* HEAT BIOLOGICS INC - ANTICIPATES RECEIVING ADDITIONAL $6.9
MILLION IN GRANT FUNDS AFTER FILING PTX-35 IND
* HEAT BIOLOGICS INC - QTRLY DILUTED SHARE LOSS $0.71
* HEAT BIOLOGICS INC - ENDED QUARTER WITH APPROXIMATELY
$23.5
MILLION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS.
Source text for Eikon: https://bit.ly/30nlNWI
Further company coverage: HTBX.O
((Briefs@thomsonreuters.com;))
Recent news on Scorpius Holdings
See all newsBrief: Scorpius Holdings Inc Files For Non Timely 10-K With U.S. SEC
Brief: Scorpius Holdings Files For Offering Up To 29.4 Million Shares Of Common Stock
Brief: Scorpius Holdings Announces Collaboration With Celltheon Corporation
Brief: Scorpius Holdings - Implementation Of Strategic Cost-Saving Measures Expected To Save Over $2 Mln Annually
Brief: Scorpius Holdings Announces Partnership With U.S. Biotech Company